ImmunoGen Beheer

Beheer criteriumcontroles 2/4

De CEO ImmunoGen is Mark Enyedy, benoemd in May2016, heeft een ambtstermijn van 7.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.42M, bestaande uit 14% salaris en 86% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.22% van de aandelen van het bedrijf, ter waarde $ 18.25M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 12.1 jaar.

Belangrijke informatie

Mark Enyedy

Algemeen directeur

US$5.4m

Totale compensatie

Percentage CEO-salaris	14.0%
Dienstverband CEO	7.8yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	12.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mark Enyedy's beloning veranderd ten opzichte van ImmunoGen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$74m
Jun 30 2023	n/a	n/a	-US$180m
Mar 31 2023	n/a	n/a	-US$240m
Dec 31 2022	US$5m	US$759k	-US$223m
Sep 30 2022	n/a	n/a	-US$201m
Jun 30 2022	n/a	n/a	-US$161m
Mar 31 2022	n/a	n/a	-US$129m
Dec 31 2021	US$7m	US$735k	-US$139m
Sep 30 2021	n/a	n/a	-US$71m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$5m	US$714k	-US$44m
Sep 30 2020	n/a	n/a	-US$71m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$89m
Dec 31 2019	US$4m	US$710k	-US$104m
Sep 30 2019	n/a	n/a	-US$151m
Jun 30 2019	n/a	n/a	-US$176m
Mar 31 2019	n/a	n/a	-US$174m
Dec 31 2018	US$9m	US$687k	-US$169m
Sep 30 2018	n/a	n/a	-US$140m
Jun 30 2018	n/a	n/a	-US$150m
Mar 31 2018	n/a	n/a	-US$117m
Dec 31 2017	US$3m	US$670k	-US$96m

Compensatie versus markt: De totale vergoeding ($USD 5.42M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 3.22M ).

Compensatie versus inkomsten: De vergoeding van Mark is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mark Enyedy (59 yo)

7.8yrs

Tenure

US$5,422,421

Compensatie

Mr. Mark Joseph Enyedy serves as Independent Director of BioMarin Pharmaceutical Inc. since December 27, 2023. He is Non-Executive Director at Ergomed plc since June 10, 2021. He has been the Chief Executi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Enyedy	President	7.8yrs	US$5.42m	0.22% $ 18.3m
Stacy Coen	Senior VP & Chief Business Officer	3.7yrs	US$1.84m	0.027% $ 2.3m
Michael Vasconcelles	Chief Medical Officer	1.2yrs	US$3.81m	0.00050% $ 41.8k
Lauren White	Senior VP & Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Anabel Chan	Head of Investor Relations	no data	geen gegevens	geen gegevens
Daniel Char	Senior VP	1.3yrs	geen gegevens	0.00037% $ 30.9k
Courtney O'Konek	Senior Director of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Audrey Bergan	Senior VP & Chief HR Officer	5.6yrs	geen gegevens	geen gegevens
Theresa Wingrove	Senior Vice President of Regulatory Affairs & Quality	no data	US$1.27m	0.0079% $ 657.0k
Isabel Kalofonos	Senior VP & Chief Commercial Officer	less than a year	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0A8K wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Enyedy	President	7.8yrs	US$5.42m	0.22% $ 18.3m
Stephen McCluski	Independent Chairman	16.8yrs	US$257.80k	0% $ 0
Dean Mitchell	Independent Director	12.1yrs	US$217.80k	0.038% $ 3.2m
Kristine Peterson	Independent Director	12.1yrs	US$227.80k	0% $ 0
Helen Thackray	Independent Director	2.4yrs	US$175.00k	0.0011% $ 96.1k
Richard Wallace	Independent Director	16.3yrs	US$220.30k	0.0037% $ 312.6k
Stuart Arbuckle	Independent Director	6.1yrs	US$210.30k	0.0020% $ 168.0k
Mark A. Goldberg	Independent Director	12.3yrs	US$225.30k	0.023% $ 1.9m
Tracey McCain	Independent Director	2.3yrs	US$146.65k	0% $ 0

12.1yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0A8K zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.1 jaar).

ImmunoGen Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insider recently sold US$1.5m worth of stock

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

President recently sold US$17m worth of stock

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

New major risk - Share price stability

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold US$1.5m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.31 loss in 3Q 2022)

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

President recently sold US$17m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

Forecast breakeven date moved forward to 2024

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.24 loss in 2Q 2022)

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.095 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd